Wellington Management

Wellington Management Company, founded in 1928 and headquartered in Boston, Massachusetts, is an investment management firm that caters to a diverse range of institutional clients, including high-net-worth individuals, pension plans, endowments, insurers, and government entities. The firm employs a comprehensive approach to investment management that encompasses equity, fixed income, currency, commodity, and alternative markets. Wellington Management offers various services, including asset allocation, multi-manager strategies, and specialized investment approaches. The firm is known for its focus on both growth and value stocks across small-cap, mid-cap, and large-cap companies, and it manages a variety of investment vehicles, such as mutual funds and hedge funds, to meet the unique needs of its clientele.

Kelly McDonnell

Vice President

Prakhar Singh

Principal, Private Equity and Sector Lead, Asia

Past deals in Series C

AssetWatch

Series C in 2025
AssetWatch specializes in proactive and predictive maintenance solutions aimed at preventing unplanned downtime for global manufacturers. The company offers an extensive remote condition monitoring service that integrates wireless sensors and communication hubs with sophisticated software. These wireless vibration and temperature sensors gather critical machine health data, which is analyzed using machine learning algorithms and the expertise of condition monitoring engineers. This analysis provides actionable insights that go beyond simple pass/fail assessments, enabling manufacturers to transition from a reactive to a proactive maintenance culture. By delivering prescriptive recommendations, AssetWatch supports manufacturers in optimizing their maintenance processes and enhancing operational reliability.

Atsena Therapeutics

Series C in 2025
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

Lumafield

Series C in 2025
Lumafield specializes in industrial computed tomography (CT) solutions, providing advanced non-destructive testing and inspection tools for engineers. The company's flagship product, the Neptune X-ray CT scanner, offers detailed imaging that allows engineers to analyze internal structures and identify defects in various materials. Complementing this hardware is the Voyager software platform, which facilitates cloud-based, AI-powered analysis, enabling automated inspections and collaborative efforts among teams. Additionally, Lumafield's Triton system is designed for high-speed scanning, catering to the needs of high-volume manufacturing environments. The company serves diverse industries, including aerospace, automotive, electronics, and medical devices, aiming to enhance product quality and reliability throughout the product development process.

SiteOne Therapeutics

Series C in 2024
SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics for the treatment of acute and chronic pain. The company aims to address the limitations of existing pain management therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, by creating safer and more effective alternatives. Their lead candidates are highly selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is crucial in the generation and conduction of pain signals. By targeting this channel, SiteOne Therapeutics seeks to provide healthcare professionals with advanced treatment options for neuropathic pain, ultimately improving patient outcomes and efficiency in pain management.

MBX Biosciences

Series C in 2024
MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Scorpion Therapeutics

Series C in 2024
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Bluejay Therapeutics

Series C in 2024
Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Zenas BioPharma

Series C in 2024
Zenas BioPharma is a clinical-stage biopharmaceutical company based in Florida, dedicated to developing immune-based therapies for patients. The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody that targets both CD19 and FcγRIIb, which are found on B cells. This innovative approach aims to inhibit the activity of B cells involved in various autoimmune diseases while preserving their overall population, thus offering a potential therapeutic advantage over traditional treatments that deplete these cells.

Asher Bio

Series C in 2024
Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Obsidian Therapeutics

Series C in 2024
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.

Quince

Series C in 2024
Quince, LLC, established in 2016 and headquartered in San Francisco, California, is a retailer specializing in affordable luxury apparel, accessories, and home goods. The company offers a wide range of products for men and women, including jewelry, clothing, and home textiles, all sourced directly from manufacturers using a just-in-time production model. This approach enables Quince to provide high-quality items at competitive prices while minimizing waste.

Avalyn Pharma

Series C in 2023
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

SKIMS

Series C in 2023
SKIMS is a brand focused on creating innovative underwear, loungewear, and shapewear designed to enhance body shape. The company manufactures and retails a diverse array of products, including bodysuits, shapewear, and various styles of underwear. SKIMS offers a broad selection of colors and sizes to cater to different body types, ensuring that women receive both the support and coverage they need. By prioritizing inclusivity and functionality, SKIMS aims to address the diverse needs of its customers in the intimate apparel market.

MUSINSA

Series C in 2023
MUSINSA is a fashion business company that offers personalized curation and storytelling for various brands and products. Its platform helps brands and consumers' lifestyles by designing, creating, enjoying, and interacting with fashion. It also delivers fashion trends and information to help customers engage and interact.

Boundless Bio

Series C in 2023
Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

AMP

Series C in 2023
AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

AMP

Series C in 2022
AMP Robotics Corporation specializes in designing and manufacturing robotic systems for material recovery facilities and recycling operations, focusing on automating the identification, sorting, and processing of complex waste streams. The company's flagship product, AMP Cortex, utilizes advanced robotics and computer vision technology to efficiently pick and sort recyclable materials, significantly lowering sorting costs. Additionally, AMP Neuron, a software solution, captures and analyzes material data to identify features in a manner similar to human perception. By leveraging artificial intelligence and machine learning, AMP Robotics enhances recycling processes for various waste types, including municipal solid waste and e-waste. The modular design of its systems allows for easy integration into existing infrastructure, minimizing disruption and capital investment. Founded in 2014 and headquartered in Louisville, Colorado, AMP Robotics has formed strategic partnerships to further its mission of improving recycling rates and economic recovery of recyclables.

Meati

Series C in 2022
Meati Foods is a Boulder, Colorado-based company specializing in the production and sale of fungi-based meat alternatives. Founded in 2016, the company aims to provide sustainable and nutritious plant-based options that serve as an alternative to traditional meat products. Meati Foods utilizes a proprietary fermentation process to create minimally processed steaks made from natural ingredients, ensuring its offerings are free from common allergens. The company markets its products online, making them accessible to a wide audience seeking vegan food choices that are both healthy and environmentally friendly.

JUSPAY

Series C in 2021
Juspay is a developer of an online platform designed to be used for mobile-based payments. The company's online platform is a SaaS layer on top of payment gateways to simplify integration, improve robustness and ease the management of diverse and rapidly evolving payment options, enabling users to make electronic transactions securely and efficiently.

Course Hero

Series C in 2021
Course Hero operates as an online learning platform dedicated to providing study resources for students and educators. Founded in 2006 and based in Redwood City, California, the company offers a range of materials including lecture notes, study guides, textbook help, practice problems, exams, and video lectures from universities across the United States and internationally. Course Hero's platform is subscription-based and includes an educator platform for distributing materials and publishing content. Additionally, it features a flashcards application and access to expert tutors who assist students with their queries. The company was previously known as TheCollegeFreeway.

Teya

Series C in 2021
Teya is a comprehensive solution tailored for small and growing businesses, offering a suite of services that facilitate efficient management and growth. The company specializes in payment processing, providing fast and secure transaction capabilities, along with cloud-native business management software. Teya's offerings include issuer payment processing and cash advance services, which assist merchants in enhancing their operations. With a commitment to supporting over 300,000 business owners, Teya enables them to effectively manage their businesses and fosters a positive experience in their entrepreneurial journey.

Strata Oncology

Series C in 2021
Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Sundae

Series C in 2021
Sundae operates a residential real estate marketplace designed to assist homeowners in selling their properties off-market. The platform caters particularly to those with dated or damaged homes, allowing sellers to bypass the traditional real estate process, which often involves cleanup, repairs, and showings. By connecting homeowners with a broad network of local investors, Sundae ensures that sellers can achieve a fair price for their properties without the unpredictability commonly associated with real estate transactions. This convenient approach enables individuals to sell their homes on their own timeline, simplifying the selling experience.

Lendbuzz

Series C in 2021
Lendbuzz, Inc. operates an innovative car financing platform that utilizes machine learning algorithms to assess the creditworthiness of individuals, particularly those with thin or no credit history. Founded in 2015 and based in Boston, Massachusetts, the company focuses on providing financing solutions for consumers who are often underserved by traditional banks, including international students, foreign professionals, and expatriates. By analyzing a range of background information—such as employment, education, and financial history—Lendbuzz is able to extend loans and refinancing options with favorable terms, regardless of credit score or the presence of a social security number. The platform partners with auto dealerships to facilitate access to financing, allowing consumers to purchase vehicles while enabling dealerships to serve a broader and more diverse client base.

NiKang Therapeutics

Series C in 2021
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Cityblock

Series C in 2021
Cityblock Health, established in 2017 and headquartered in Brooklyn, New York, operates a personalized health system tailored to meet the unmet health and social needs of Medicaid and Medicare populations. The company's online platform offers integrated primary care, behavioral health, and virtual care services, along with a communication and task management tool called Commons. Cityblock's model focuses on prevention-oriented care and collaboration with community-based organizations to deliver personalized care to low-income urban residents. During the COVID-19 pandemic, the company developed a risk assessment model to identify high-risk members within its network.

Affinivax

Series C in 2021
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Cityblock

Series C in 2020
Cityblock Health, established in 2017 and headquartered in Brooklyn, New York, operates a personalized health system tailored to meet the unmet health and social needs of Medicaid and Medicare populations. The company's online platform offers integrated primary care, behavioral health, and virtual care services, along with a communication and task management tool called Commons. Cityblock's model focuses on prevention-oriented care and collaboration with community-based organizations to deliver personalized care to low-income urban residents. During the COVID-19 pandemic, the company developed a risk assessment model to identify high-risk members within its network.

Edgewise Therapeutics

Series C in 2020
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

Current

Series C in 2020
Current is a consumer fintech banking platform dedicated to enhancing financial access for everyday Americans. The company focuses on developing integrated solutions that address the barriers preventing individuals from achieving their financial goals. By simplifying banking processes and providing user-friendly tools, Current aims to empower users to build a secure financial future. With backing from prominent investors, Current continues to innovate in the financial technology space, striving to meet the diverse needs of its customer base through modern banking solutions.

Gracell Biotechnologies

Series C in 2020
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing cell therapies for cancer treatment. The company’s lead product candidates include GC012F, a dual-target autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia and is also being investigated for relapsed or refractory B cell non-Hodgkin’s lymphoma. Additionally, Gracell is developing GC007F for B cell non-Hodgkin's lymphoma and GC027, an allogeneic CAR-T product candidate for adult T cell acute lymphoblastic leukemia. The company also has GC007g, a donor-derived therapy for relapsed or refractory B cell acute lymphoblastic leukemia, and a pipeline of earlier stage candidates targeting other cancer types, including ovarian cancer and breast cancer. Founded in 2017, Gracell aims to provide innovative cellular therapeutics that enhance treatment options for patients suffering from various hematological malignancies and solid tumors.

Olema Oncology

Series C in 2020
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

Novellus

Series C in 2020
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics

Series C in 2020
Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Freeline Therapeutics

Series C in 2020
Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, aiming to express functional proteins in the patient's bloodstream. Freeline's advanced product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, Freeline offers expertise in CMC process development, analytics, and AAV technologies.

Kymera Therapeutics

Series C in 2020
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Generation Bio

Series C in 2020
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Black Diamond Therapeutics

Series C in 2019
Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.

Atreca

Series C in 2018
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.

Arcus Biosciences

Series C in 2017
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

Nightstar Therapeutics

Series C in 2017
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.

Mersana Therapeutics

Series C in 2016
Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Kala Pharmaceuticals

Series C in 2016
Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

The Trade Desk

Series C in 2016
The Trade Desk, Inc. is a technology company that operates a self-service cloud-based platform designed for advertisers and advertising agencies. Founded in 2009 and headquartered in Ventura, California, the company enables users to create, manage, and optimize data-driven digital advertising campaigns across a variety of formats, including display, video, audio, native, and social. Its platform supports multiple devices, such as computers, mobile devices, and connected TVs. By leveraging data analytics, The Trade Desk helps clients enhance the effectiveness of their advertising efforts. The company generates revenue through fees that are based on a percentage of its clients' advertising expenditures.

Magic Leap

Series C in 2016
Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Allena Pharmaceuticals

Series C in 2015
Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.

Rubicon

Series C in 2015
Rubicon is a digital marketplace for waste and recycling. They provide innovative software-based products for businesses and governments. They focus on developing software solutions that bring new transparency to the waste and recycling industry, encouraging customers to make data-driven decisions that lead to more efficient and effective operations as well as more sustainable outcomes.

TabbedOut

Series C in 2015
TabbedOut puts you in control of your tab at bars and restaurants. Say goodbye to end-of-night bar lines, and flagging down your server when you’re ready to settle the bill. Never leave your card at the bar again! TabbedOut is easier and more secure than handing over your credit card to a stranger. Open a tab, view the running total, and pay for it instantly (and securely) all from your phone. You can even split your tab among friends, post to Facebook or Twitter to let your friends know where you’re dining, send a positive or negative review of your experience, and get offers sent from your favorite venue straight to your phone. TabbedOut takes the hassle out of dining out for good. We are adding new locations every day, so check in often on the locations screen. Don’t see your favorite bar or restaurant on the list? Let us know! Tweet at or Facebook us at @tabbedout. For merchants: TabbedOut is the premier marketing and analytics platform built exclusively for the hospitality industry and powered by mobile payments. We allow our merchants real time insight into their customers through our proprietary software system that tracks spending habits, product preferences, customer feedback and loyalty rewards. Best of all, TabbedOut allows you, the merchant, to accept mobile payments integrated into your POS system. Finally, POS systems and mobile payments meet customer marketing and rewards in real time. That’s the power of TabbedOut! Free to download and no hidden fees.

Harry's

Series C in 2015
Harry's Inc., established in 2012 and headquartered in New York, specializes in manufacturing and selling men's grooming products. The company produces a range of shaving items including razors, creams, kits, and face care products. Harry's operates an online platform where consumers can purchase these products individually or via a subscription service for convenient access to their grooming essentials.

Oscar Health

Series C in 2015
Oscar Health is a health insurance company based in New York, founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser. It specializes in offering individual and family health insurance plans, Medicare Advantage programs for seniors, and small group products. Oscar Health aims to enhance the healthcare experience by leveraging technology, design, and data to make services more accessible and user-friendly. The company primarily serves individuals, couples, and families who do not receive employer-sponsored health insurance in select states, including New York, New Jersey, California, and Texas. In addition to traditional insurance offerings, Oscar provides virtual care, doctor support, and appointment scheduling, emphasizing a comprehensive approach to healthcare management.

Blueprint Medicines

Series C in 2014
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Powa Technologies

Series C in 2014
Powa Technologies is an international commerce specialist based in London, United Kingdom, that focuses on integrating physical and digital retail experiences. The company offers a suite of technologies designed to enhance e-commerce, including PowaTag, a mobile application that facilitates payments through codes that can be applied to various marketing media such as billboards and advertisements. In addition to PowaTag, Powa Technologies provides several other products, including PowaWeb, powaPos, and PowaPIN, which collectively support the development of scalable online shops and enable an agile e-commerce environment. Established in 2007, Powa Technologies operates as a subsidiary of SuperCom Ltd.

The Honest Company

Series C in 2014
The Honest Company, Inc. is a consumer products firm based in Santa Monica, California, established in 2011. It specializes in designing and manufacturing a diverse range of eco-friendly and affordable products aimed at families and homes. The company's offerings include bundles for babies, bath and body care, cleaning supplies, and health and wellness products. Prominent items in their portfolio consist of eco-friendly diapers and wipes, skincare products, household cleaners, and organic nutritional supplements. The Honest Company operates through both retail and digital channels, ensuring broad accessibility for consumers. Its revenue is primarily driven by the sale of diapers and wipes, emphasizing the brand's commitment to convenience and sustainability.

Civitas Therapeutics

Series C in 2014
Civitas Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pulmonary delivery therapies. Utilizing its proprietary ARCUS technology, the company creates therapeutics aimed at treating central nervous system and respiratory disorders. Civitas Therapeutics serves patients across the United States, focusing on delivering transformative treatment options to improve health outcomes.

Datalogix

Series C in 2014
Datalogix is a prominent company specializing in connecting digital media with offline purchasing data, enabling marketers to enhance the effectiveness and measurability of their advertising efforts. The company serves more than half of the top 100 consumer marketers and manages the DLX Platform, which encompasses over $1 trillion in consumer spending and supports campaigns for a significant majority of online media companies. Datalogix's DLX ROI is becoming a standard for measuring the impact of digital media on offline sales. Additionally, the company provides predictive analytics for direct mail and integrated media solutions through the DLX Net. Its expertise covers various consumer sectors, including retail, consumer packaged goods, automotive, telecommunications, travel, and financial services. Headquartered in Colorado, Datalogix has established offices in key cities such as New York City, San Francisco, Boston, Chicago, Detroit, and London.

Malauzai

Series C in 2014
Malauzai Software, Inc., established in 2009 and headquartered in Austin, Texas, specializes in developing mobile and internet banking solutions tailored for community financial institutions. The company offers a suite of SmartApps, SmartwebApps, and SmartwearApps, catering to consumers, small businesses, and employees, enabling them to manage their financial transactions across various devices. Malauzai's flagship product, the MOX enterprise platform, streamlines management of these solutions on a single platform. The company's products aim to enhance the customer experience and increase value for financial institutions, focusing primarily on community banks and credit unions. Since 2018, Malauzai has operated as a subsidiary of Finastra Group Holdings Limited.

SensABLE Technologies

Series C in 2000
SensAble Technologies, Inc. specializes in force-feedback haptic devices and touch-enabled 3D modeling software solutions. Its key products include FreeForm Modeling Systems, designed for applications in medical and dental modeling, product design, and fine arts, as well as The SensAble Dental Lab System, which facilitates digital scanning, 3D modeling, and fabrication. The company also produces PHANTOM Haptic Devices for enhanced 3D navigation and virtual workspaces, along with OpenHaptics, a toolkit for developing haptic applications. SensAble Technologies serves a wide array of industries, including automotive, dental, fine arts, gaming, and medical sectors. Its products are utilized in various applications such as product design, surgical simulation, and research. Founded in 1993 and based in Woburn, Massachusetts, SensAble Technologies also maintains a sales office in Tokyo, Japan, distributing its solutions through direct sales and reseller channels.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.